

November 15, 1990






Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

VOLUME 50 • NO. 22 • PP 7093-7413

ISSN 0008-5472 • CNREA 8



**POSITION AVAILABLE:
Assistant Professor (Tenure Track) Cancer Cytogenetics
Department of Laboratory Medicine & Pathology
University of Minnesota**

A tenure-track faculty position is available for candidates with an M.D. or Ph.D. degree in genetics or a closely related discipline with research and/or clinical experience in human cancer cytogenetics required. Board certification or eligibility in Clinical Cytogenetics is desirable. Demonstration of scholarly achievement and research productivity is necessary.

Responsibilities will include didactic teaching/training of residents, medical students, graduate students, postdoctoral fellows, and medical technologists. The successful candidate will be expected to develop an independent research program in cytogenetics. Service responsibilities will include assisting in the direction of the clinical cytogenetics laboratory (limited administrative duties) with primary emphasis on non-hematologic solid tumors.

Deadline for receipt of applications is March 31, 1991. Applicants please send curriculum vitae, names of three references and a brief synopsis of recent research activities to:

Harry Orr, Ph.D.
Chair, Cytogenetics Search Committee
Department of Laboratory Medicine and Pathology
Box 198 UMHC, 420 Delaware Street SE
Minneapolis, MN 55455

The University of Minnesota is an equal opportunity educator and employer, and specifically invites and encourages applications from women and minorities.

**CLINICAL PHARMACIST/
PHARMACOLOGIST**


*Ontario Cancer Institute/Faculty of Pharmacy
UNIVERSITY OF TORONTO*

Applications are invited for a scientist position from clinical pharmacists/pharmacologists with experience in pharmacokinetics, analysis of drugs in biological fluids, therapeutic drug monitoring and drug trial design. The successful candidate will be expected to develop a research focus which is complementary to the ongoing clinical pharmacology program of Phase I and II trials of new antineoplastic and anti-emetic agents in the cancer population. Assistance with research activities of Pharmacy, Nursing and Medical staff in a consultative role will be encouraged. The candidate will also be expected to be involved in the teaching programs of the Faculty of Pharmacy and The Ontario Cancer Institute.

The successful candidate should hold a Pharm.D. or a Ph.D. degree and have relevant research experience. A university appointment commensurate with candidate's experience is available. Interested persons should submit a current curriculum vitae, a short outline of future research interests and the name of three references to: Dr. C. Erlichman, Ontario Cancer Institute, 500 Sherbourne Street, Toronto, Ontario, Canada M4X 1K9.

Applications should be submitted by January 4, 1991.

In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents. In accordance with the Employment Equity Policy of the University of Toronto and The Ontario Cancer Institute, applications are invited from all qualified women and men.



THE

Ontario Cancer

• INSTITUTE •



AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Membrane Transport in Multidrug Resistance, Development, and Disease

(co-sponsored by the National Cancer Institute of Canada)

March 10-14, 1991
Banff Centre, Banff, Alberta, Canada

CONFERENCE COCHAIRPERSONS

SUSAN B. HORWITZ / Bronx, NY VICTOR LING / Toronto, Ontario, Canada

PROGRAM COMMITTEE

GIOVANNA F.-L. AMES / Berkeley, CA CAROL E. CASS / Edmonton, Alberta, Canada
ANNA MARIA CASAZZA / Wallingford, CT PHILIPPE GROS / Montreal, Quebec, Canada
JOHN RIORDAN / Toronto, Ontario, Canada

SCIENTIFIC PROGRAM

The Future of Medical Genetics

VICTOR LING / Toronto, Canada
LOUIS SIMINOVITCH / Toronto, Canada

Phosphorylation and Signal Transduction

I. BERNARD WEINSTEIN / New York, NY
DAVID L. GARBERS / Nashville, TN
RANDALL R. REED / Baltimore, MD

Membrane Pumps and Channels

WILLIAM T. BECK / Memphis, TN
WILLIAM A. CATTERALL / Seattle, WA
HARVEY F. LODISH / Cambridge, MA
REINHART A. F. REITHMEIER / Toronto, Canada

Multidrug Resistance

SUSAN B. HORWITZ / Bronx, NY
IGOR B. RONINSON / Chicago, IL
TAKASHI TSURUO / Tokyo, Japan
MICHAEL M. GOTTESMAN / Bethesda, MD
BRUCE A. CHABNER / Bethesda, MD

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
Sixth and Chestnut Streets
Philadelphia, PA 19106
215-440-9300 215-440-9313 (FAX)

The Cystic Fibrosis Gene and Its Product

RICHARD BOUCHER / Chapel Hill, NC
LAP-CHEE TSUI / Toronto, Canada
MICHAEL J. WELSH / Iowa City, IA
JOHN R. RIORDAN / Toronto, Canada

P-Glycoprotein Homologs and Development

PHILIPPE GROS / Montreal, Canada
PIET BORST / Amsterdam, Netherlands
JEREMY THORNER / Berkeley, CA
JAMES M. CROOP / Boston, MA
ALAN COWMAN / Melbourne, Australia

Metabolite and Drug Transport

ALAN R. P. PATERSON / Edmonton, Canada
CAROL E. CASS / Edmonton, Canada
I. DAVID GOLDMAN / Richmond, VA
STEPHEN B. HOWELL / La Jolla, CA
SHIMON SCHULDINER / Jerusalem, Israel


Permease Systems in Bacteria and Eukaryotes

ERNEST M. WRIGHT / Los Angeles, CA
GIOVANNA F.-L. AMES / Berkeley, CA
H. RONALD KABACK / Los Angeles, CA

Application Deadline:
December 3, 1990

Late applications will be accepted on a space-available basis.

COVER LEGEND



Among the major awards for outstanding contributions to cancer research are those of the Armand Hammer Foundation, supported by Armand Hammer, who was featured on the cover of the February 1, 1988 issue of *Cancer Research*. This fabulous businessman, entrepreneur, art collector, and philanthropist has been a strong supporter of cancer research and has served on the President's Cancer Panel since 1981. The annual award of \$100,000 for 1989 was shared by Dr. Vincent T. DeVita, Jr., *left*, and Dr. Emil Frei III, *right*. Both are distinguished figures in clinical oncology.

Dr. Vincent DeVita, Jr. received the M.D. degree with distinction from George Washington University School of Medicine in 1961. After residencies at George Washington, 1961–1963; National Cancer Institute (NCI), 1963–1965; and Yale-New Haven Medical Center, 1965–1966, he returned to the NCI and rose there from head of the Solid Tumor Service to Chief, Medicine Branch; Director, Division of Cancer Treatment; Clinical Director; and Director of the NCI from 1980 to 1988. He is currently Physician-in-Chief and Benno C. Schmidt Professor in Clinical Oncology, Memorial Sloan-Kettering Cancer Center. He is also Professor of Medicine at George Washington and Cornell Medical Colleges, is on the consulting medical staff of the Naval Medical Center in Bethesda, and is Visiting Physician at Rockefeller University Hospital in New York. He is the author of many papers and books on clinical oncology.

Dr. DeVita has served the field of clinical oncology through an extraordinary number of editorial boards,

advisory panels, officerships, and committees, and his numerous honors include honorary memberships in foreign societies, lectureships, awards, and honorary degrees from the College of William and Mary, Ohio State University, George Washington University School of Medicine, New York Medical College, and Georgetown University. He is author and coauthor of over 400 articles, book chapters, and reviews and is coauthor, with Hellman and Rosenberg, of *Cancer: Principles and Practice of Oncology* (Philadelphia: Lippincott), now in its third edition.

Dr. DeVita was cited by the Armand Hammer Foundation for his “pioneering development of combination chemotherapy for the curative treatment of Hodgkin’s disease, for his continued contributions to the development of principles of combination chemotherapy, and for his inspired leadership of the National Cancer Program during his tenure as director of the National Cancer Institute.”

Dr. Emil Frei III received the M.D. from Yale University School of Medicine in 1948, and after residencies at St. Louis and Washington University Medical Schools, he joined the National Cancer Institute. He rose there from Senior Investigator to Head of the Medical Service; to Chief, Medicine Branch; to Associate Scientific Director for Experimental Therapeutics. From 1965 to 1972 he was Associate Scientific Director and Head, Department of Experimental Therapeutics at M. D. Anderson Cancer Center in Houston. Since 1973, he has served as Director and Physician-in-Chief, Dana-Farber Cancer Institute, Boston. He also holds appointments at Children’s Hospital, Brigham and Women’s, Beth Israel, and New England Deaconess in Boston; MIT in Cambridge; and Eastern Maine Medical Center in Bangor. He has held numerous professional and visiting consultants and lectureships and has served on many professional society committees, offices, study sections, study panels, and editorial boards. He has been honored by numerous awards including the Kettering Prize of the General Motors Cancer Research Foundation, the Annual National Award of the American Cancer Society, the Lasker Award, and the Man of the Year Award of the Leukemia Society. He has served as President of the AACR, 1971–1972, and ASCO, 1968–1969. He is a member of the Institute of Medicine of the National Academy of Sciences.

His award was given “for the development of combination chemotherapy for the curative treatment of leukemia and his many contributions to understanding the mechanisms of action of combination chemotherapy of cancer.”

Sidney Weinhouse